Abstract
Due to minimal treatment success with surgery, radiotherapy, and chemotherapy, the aim of this study was to test the therapeutic potential of gene therapy for the treatment of glioblastoma multiforme (GBM). We have quantitatively analyzed two gene therapy approaches using short-term human glioma cell cultures derived from surgical biopsies (designated IN859, IN1612, IN2045, IN1760, and IN1265) and compared the results of gene therapy with the chemosensitivity of the same cells. All of the glioma cell cultures tested were susceptible to recombinant adenovirus (RAd)-mediated infection. Expression of herpes simplex virus type 1-thymidine kinase (RAd128), followed by ganciclovir treatment, induced apoptosis in all of the glioma cell cultures studied, including three that are resistant to the chemotherapeutic drug 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU). Expression of murine Fas ligand (RAdhCMV-mFasL) also induced cell death in four of the five cell cultures studied. One cell culture that was resistant to CCNU was also resistant to apoptosis induced by mFasL expression. These results suggest that sensitivity to chemotherapeutic agents does not necessarily correlate with the sensitivity to gene therapy treatments. RAds expressing therapeutic gene products in human glioma cell cultures are able to induce apoptosis even in some cells that are resistant to a commonly used chemotherapeutic agent. Therefore, RAd-mediated gene transfer could be a good candidate to further develop gene therapy for the treatment of GBM. Cancer Gene Therapy (2001) 8, 589–598
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kleihues P, Burger PC, Scheithauer BW . The new WHO classification of brain tumors Brain Pathol 1993 3: 255–268
Holland EC . Glioblastoma multiforme: the terminator Proc Natl Acad Sci USA 2000 97: 6242–6244
Eck SL, Alavi JB, Alavi A, et al . Treatment of advanced CNS malignancies with the recombinant adenovirus H5.010RSVTK: a phase I trial Hum Gene Ther 1996 7: 1465–1482
Bradford R, Koppel H, Pilkington GJ, et al . Heterogeneity of chemosensitivity in six clonal cell lines derived from a spontaneous murine astrocytoma and its relationship to genotypic and phenotypic characteristics J Neuro-Oncol 1997 34: 247–261
Klatzmann D, Valery CA, Bensimon G, et al . A phase I/II study of herpes simplex type 1 thymidine kinase ‘suicide’ gene therapy for recurrent glioblastoma Hum Gene Ther 1998 9: 2595–2604
Palu G, Cavaggioni A, Calvi P, et al . Gene therapy of glioblastoma multiforme via combined expression of suicide and cytokine genes: a pilot study in humans Gene Ther 1999 6: 330–337
Shand N, Weber F, Mariani L, et al . A phase 1–2 clinical trial of gene therapy for recurrent glioblastoma multiforme by tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir Hum Gene Ther 1999 10: 2325–2335
Trask TW, Trask RP, Aguilar-Cordova E, et al . Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with recurrent malignant brain tumors Mol Ther 2000 1: 195–203
Market JM, Medlock MD, Rabkin SD, et al . Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial Gene Ther 2000 7: 867–874
Rampling R, Cruickshank G, Papanastassiou V, et al . Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma Gene Ther 2000 7: 859–866
Sandmair A-M, Loimas S, Puranen P, et al . Thymidine kinase gene therapy for human malignant glioma using replication-deficient retroviruses or adenoviruses Hum Gene Ther 2000 11: 2197–2206
Castro MG, Cowen R, Smith-Arica J, et al . Gene therapy strategies for intracranial tumours: glioma and pituitary adenomas Histol Histopathol 2000 15: 1233–1252
Chen S-H, Shine HD, Goodman J, et al . Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo Proc Natl Acad Sci USA 1994 91: 3054–3057
Maron A, Gustin T, Le Roux A, et al . Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene: long-term follow-up by magnetic resonance imaging Gene Ther 1996 3: 315–322
Dewey RA, Morrissey G, Cowsill CM, et al . Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials Nat Med 1999 5: 1256–1263
Sturtz FG, Waddell K, Shulok J, et al . Variable efficiency of the thymidine kinase/ganciclovir system in human glioblastoma cell lines: implications for gene therapy Hum Gene Ther 1997 8: 1945–1953
Vandier D, Rixe O, Brenner M, et al . Selective killing of glioma cell lines using an astrocyte-specific expression of the herpes simplex virus-thymidine kinase gene Cancer Res 1998 58: 4577–4580
Shinoura N, Yoshida Y, Sadata A, et al . Apoptosis by retrovirus- and adenovirus-mediated gene transfer of fas ligand to glioma cells: implications for gene therapy Hum Gene Ther 1998 9: 1983–1993
Ambar BB, Frei K, Malipiero U, et al . Treatment of experimental glioma by administration of adenoviral vectors expressing fas ligand Hum Gene Ther 1999 10: 1641–1648
Shinoura N, Yoshida Y, Asai A, et al . Adenovirus-mediated transfer of p53 and fas ligand drastically enhances apoptosis in gliomas Cancer Gene Ther 2000 7: 732–738
Darling JL . The in vitro biology of human brain tumours In: Thomas DGT, ed. Neuro-Oncology: Primary Malignant Brain Tumours London: Edward Arnold 1990 1–25
Darling JL . Brain In: Masters JRW, ed. Human Cancer in Primary Culture: A Handbook Dordrecht: Kluwer 1991 231–251
Darling JL, Lewandowicz GM, Thomas DGT . Chemosensitivity testing human malignant brain tumors In: Kornblith PL, Walker MD, eds. Advances in Neuro-Oncology II Armonk, NY: Futura Publishing Company 1997 413–434
Wilkinson GWG, Akrigg A . The cytomegalovirus major immediate early promoter and its use in eukaryotic expression systems In: Greenaway PJ, ed. Advances in Gene Technology Vol. 2: London: JAI Press 1991 287–310
Shering AF, Bain D, Stewart K, et al . Cell-type specific expression in brain cell cultures from a short human cytomegalovirus major immediate early promoter depends on whether it is inserted into herpesvirus or adenovirus vectors J Gen Virol 1997 78: 445–459
Cowsill C, Southgate TD, Morrissey G, et al . Central nervous system toxicity of two adenoviral vectors encoding variants of the herpes simplex virus type 1 thymidine kinase: reduced cytotoxicity of a truncated HSV1-TK Gene Ther 2000 7: 679–685
Larregina AT, Morelli AE, Dewey RA, et al . FasL induces fas/apo1-mediated apoptosis in human embryonic kidney 293 cells routinely used to generate E1-deleted adenoviral vectors Gene Ther 1998 5: 563–568
Morelli AE, Larregina AT, Smith-Arica J, et al . Neuronal and glial cell type-specific promoters within adenovirus recombinants restrict the expression of the apoptosis-inducing molecule fas ligand to predetermined brain cell types, and abolish peripheral liver toxicity J Gen Virol 1999 80: 571–583
Lowenstein PR, Shering AF, Bain D, et al . The use of adenovirus vectors to transfer genes to identified target brain cells in vitro In: Lowenstein PR, Enquist LW, eds. Protocols for Gene Transfer in Neuroscience: Towards Gene Therapy of Neurological Disorders Chichester, UK: John Wiley and Sons, Ltd 1996 93–114
Southgate TD, Kingston PA, Castro MG . Gene transfer into neural cells in vitro using adenoviral vectors In: Crawley J, Rogawski M, Sibley D, Wray S, Skolnick P, eds. Current Protocols in Neuroscience, Vol. 4: Gene Cloning, Expression, and Mutagenesis New York, NY: John Wiley and Sons Inc 2000 4.23.1–4.23.40
Dion LD, Fang J, Garver RI Jr . Supernatant rescue assay vs. polymerase chain reaction for detection of wild type adenovirus-contaminating recombinant adenovirus stocks J Virol Methods 1996 56: 99–107
Rubinchik S, Ding R, Qiu AJ, et al . Adenoviral vector which delivers fasL-GFP fusion protein regulated by the tet-inducible expression system Gene Ther 2000 7: 875–885
Southgate TD, Windeatt S, Smith-Arica J, et al . Transcriptional targeting to anterior pituitary lactotrophic cells using recombinant adenovirus vector in vitro and in vivo in normal and estrogen/sulpiride-induced hyperplasic anterior pituitaries Endocrinology 2000 141: 1–13
Macgregor GR, Nolan GP, Fiering S, et al . Use of E. coli lacZ (β-galactosidase) as a reporter gene In: Murray EJ, ed. Methods in Molecular Biology, Vol. 7: Gene Transfer and Expression Protocols Clifton, NJ: The Humana Press Inc 1991 217–235
Windeatt S, Southgate TD, Dewey RA, et al . Adenovirus-mediated herpes simplex virus type-1 thymidine kinase gene therapy suppresses oestrogen-induced pituitary prolactinomas J Clin Endocrinol Metab 2000 85: 1296–1305
Fraker PJ, King LE, Lill-Elghanian D, et al . Quantification of apoptotic events in pure and heterogeneous populations of cells using the flow cytometer Methods Cell Biol 1995 46: 57–76
Haselsberger K, Peterson DC, Thomas DGT, et al . Assay of anticancer drugs in tissue culture: comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma Anti-Cancer Drugs 1996 7: 331–338
El-Deredy W, Ashmore SM, Branston NM, et al . Pretreatment prediction of the chemotherapeutic response of human glioma cell cultures using nuclear magnetic resonance spectroscopy and artificial neural networks Cancer Res 1997 57: 4196–4199
Levin VA . Clinical pharmacology of the nitrosoureas In: Prestayko AW, Crooke ST, Baker LH, Carter SK, Schein PS, eds. Nitrosoureas New York, NY: Academic Press 1981 171–180
Elshami AA, Saavedra A, Zhang H, et al . Gap junctions play a role in the bystander effect of the herpesvirus thymidine kinase ganciclovir system in vitro Gene Ther 1996 3: 85–92
Freeman SM, Abboud CN, Whartenby KA, et al . The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified Cancer Res 1993 53: 5274–5283
Salomon B, Maury S, Loubiere L, et al . A truncated herpes simplex virus thymidine kinase phosphorylates thymidine and nucleoside analogs and does not cause sterility in transgenic mice Mol Cell Biol 1995 15: 5322–5328
Nagata S . Apoptosis by death factor Cell 1997 88: 355–365
Shinohara H, Yagita H, Ikawa Y, et al . Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation Cancer Res 2000 60: 1766–1772
O'Connell J, O'Sullivan GC, Collins JK, et al . The Fas counter-attack: Fas mediated T cell killing by colon cancer cells expressing Fas ligand J Exp Med 1996 184: 1075–1082
Hahne M, Rimoldi D, Schroter M, et al . Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape Science 1996 274: 1363–1366
Gerdes CA, Castro MG, Lowenstein PR . Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo Mol Ther 2000 2: 330–338
Smith-Arica JR, Morelli AE, Larregina AT, et al . Cell-type specific and regulatable transgenesis in the adult brain: adenovirus-encoded combined transcriptional targeting and inducible transgene expression Mol Ther 2000 2: 579–587
Thomas CE, Schiedner G, Kochanek S, et al . Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals infected intracranially with first-generation, but not with high-capacity, adenovirus vectors: toward realistic long-term neurological gene therapy for chronic diseases Proc Natl Acad Sci USA 2000 97: 7482–7487
Khuri FR, Nemunaitis J, Ganly I, et al . A controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer Nat Med 2000 6: 879–885
Acknowledgements
We thank Emma Jones and Clare Thomas for preparations of RAd35, M. Janicot (Rhone-Poulenc-Rorer, France) for the TK antibody, and A. Tasinato (University Hospital, Zurich, Switzerland) for the human glioma cell line LN18. We also acknowledge Ros Poulton for expert secretarial assistance.
This work was supported by the Biotechnology and Biological Sciences Research Council (UK), The Cancer Research Campaign (UK), and The Royal Society through grants to M. G. C. and P. R. L. P. R. L. is a fellow of The Lister Institute of Preventive Medicine.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Maleniak, T., Darling, J., Lowenstein, P. et al. Adenovirus-mediated expression of HSV1-TK or Fas ligand induces cell death in primary human glioma-derived cell cultures that are resistant to the chemotherapeutic agent CCNU. Cancer Gene Ther 8, 589–598 (2001). https://doi.org/10.1038/sj.cgt.7700348
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700348
Keywords
This article is cited by
-
Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside
Journal of Neuro-Oncology (2009)
-
Intracranial glioblastoma models in preclinical neuro-oncology: neuropathological characterization and tumor progression
Journal of Neuro-Oncology (2007)
-
Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors
Gene Therapy (2005)
-
FAS Associated Phosphatase (FAP-1) Blocks Apoptosis of Astrocytomas through Dephosphorylation of FAS
Journal of Neuro-Oncology (2005)
-
Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications
Journal of Neuro-Oncology (2004)